GeneOne Life Science, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 4,591.95 million compared to KRW 7,357.15 million a year ago. Net loss was KRW 5,501.3 million compared to KRW 3,347.9 million a year ago. Basic loss per share from continuing operations was KRW 81.3333 compared to KRW 50.6667 a year ago. Diluted loss per share from continuing operations was KRW 81.3333. Basic loss per share was KRW 81.3333 compared to KRW 38.6667 a year ago. For the nine months, sales was KRW 18,445.25 million compared to KRW 19,907.71 million a year ago. Net loss was KRW 13,615.32 million compared to KRW 9,103.39 million a year ago. Basic loss per share from continuing operations was KRW 202 compared to KRW 160 a year ago. Diluted loss per share from continuing operations was KRW 202 compared to KRW 160 a year ago. Basic loss per share was KRW 202 compared to KRW 160 a year ago.